AR031457A1 - METHOD FOR DETERMINING A THERAPEUTIC REGIME THROUGH THE ANALYSIS OF GENE EXPRESSION IN PRIMARY TUMORS - Google Patents

METHOD FOR DETERMINING A THERAPEUTIC REGIME THROUGH THE ANALYSIS OF GENE EXPRESSION IN PRIMARY TUMORS

Info

Publication number
AR031457A1
AR031457A1 ARP010105617A ARP010105617A AR031457A1 AR 031457 A1 AR031457 A1 AR 031457A1 AR P010105617 A ARP010105617 A AR P010105617A AR P010105617 A ARP010105617 A AR P010105617A AR 031457 A1 AR031457 A1 AR 031457A1
Authority
AR
Argentina
Prior art keywords
determining
gene expression
gene
tumor
analysis
Prior art date
Application number
ARP010105617A
Other languages
Spanish (es)
Original Assignee
Response Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/877,178 external-priority patent/US7049059B2/en
Priority claimed from US09/877,177 external-priority patent/US6582919B2/en
Priority claimed from US09/879,217 external-priority patent/US7005278B2/en
Priority claimed from US09/988,784 external-priority patent/US6602670B2/en
Application filed by Response Genetics Inc filed Critical Response Genetics Inc
Publication of AR031457A1 publication Critical patent/AR031457A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Abstract

Un método para determinar un régimen quimioterapéutico para un individuo, que comprende obtener una muestra de ARNm de un espécimen de tumor primario, determinar un nivel de expresion génica para un determinante génico de tumor en el espécimen; comparar el nivel de expresion génico para el determinante génico tumoral con un valor umbral predeterminado para ese gen e idear un régimen quimioterapéutico que comprende un agente quimioterapéutico apropiado para el determinante génico tumoral a fin de tratar las metástasis tumorales.A method for determining a chemotherapeutic regimen for an individual, which comprises obtaining a mRNA sample from a primary tumor specimen, determining a level of gene expression for a gene determinant of tumor in the specimen; compare the level of gene expression for the tumor gene determinant with a predetermined threshold value for that gene and devise a chemotherapeutic regimen comprising an appropriate chemotherapeutic agent for the tumor gene determinant in order to treat tumor metastases.

ARP010105617A 2000-12-01 2001-12-03 METHOD FOR DETERMINING A THERAPEUTIC REGIME THROUGH THE ANALYSIS OF GENE EXPRESSION IN PRIMARY TUMORS AR031457A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US25012000P 2000-12-01 2000-12-01
US25047200P 2000-12-04 2000-12-04
US09/877,178 US7049059B2 (en) 2000-12-01 2001-06-11 Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression
US09/877,177 US6582919B2 (en) 2001-06-11 2001-06-11 Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US09/879,217 US7005278B2 (en) 2001-03-02 2001-06-13 Method of determining dihydropyrimidine dehydrogenase gene expression
US09/988,784 US6602670B2 (en) 2000-12-01 2001-11-20 Method of determining a chemotherapeutic regimen based on ERCC1 expression

Publications (1)

Publication Number Publication Date
AR031457A1 true AR031457A1 (en) 2003-09-24

Family

ID=27559369

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010105617A AR031457A1 (en) 2000-12-01 2001-12-03 METHOD FOR DETERMINING A THERAPEUTIC REGIME THROUGH THE ANALYSIS OF GENE EXPRESSION IN PRIMARY TUMORS

Country Status (4)

Country Link
AR (1) AR031457A1 (en)
AU (1) AU2002220012A1 (en)
TW (1) TWI319010B (en)
WO (1) WO2002044423A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102220414A (en) * 2000-12-01 2011-10-19 应答遗传公司 Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates
US7005278B2 (en) * 2001-03-02 2006-02-28 Danenberg Kathleen D Method of determining dihydropyrimidine dehydrogenase gene expression
US6956111B2 (en) 2001-03-02 2005-10-18 Response Genetics, Inc. Method of determining dihydropyrimidine dehydrogenase gene expression
US6686155B2 (en) 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
WO2014210611A1 (en) * 2013-06-28 2014-12-31 Nantomics, Llc Pathway analysis for identification of diagnostic tests

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5952202A (en) * 1998-03-26 1999-09-14 The Perkin Elmer Corporation Methods using exogenous, internal controls and analogue blocks during nucleic acid amplification

Also Published As

Publication number Publication date
AU2002220012A1 (en) 2002-06-11
WO2002044423A2 (en) 2002-06-06
WO2002044423A3 (en) 2003-09-12
TWI319010B (en) 2010-01-01

Similar Documents

Publication Publication Date Title
AR071957A2 (en) IN VITRO METHOD FOR THE DETERMINATION OF A CHEMOTHERAPY REGIME
Casali et al. Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group intergroup randomized trial in collaboration with the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas
ES2529147T3 (en) Method for using histone deacetylase inhibitors and monitoring biomarkers in combination therapy
Liu et al. Vimentin is a potential prognostic factor for tongue squamous cell carcinoma among five epithelial–mesenchymal transition-related proteins
del Muro et al. p53 and p21 Expression levels predict organ preservation and survival in invasive bladder carcinoma treated with a combined‐modality approach
AR031455A1 (en) METHOD FOR DETERMINING A CHEMOTHERAPEUTIC REGIME BASED ON ERCC1 EXPRESSION
ES2570359T3 (en) Ultraconserved regions encoding RNAnc
Yuan et al. TREM-1 is induced in tumor associated macrophages by cyclo-oxygenase pathway in human non-small cell lung cancer
ES2494915T3 (en) Natural P53 as a biomarker for treatment with mTOR inhibitors in combination with a cytotoxic agent
Liu et al. Binding of the monoclonal antibody RP 215 to immunoglobulin G in metastatic lung adenocarcinomas is correlated with poor prognosis
Arima et al. Nuclear translocation of ADAM‐10 contributes to the pathogenesis and progression of human prostate cancer
Khan et al. Association between pretreatment haemoglobin levels and morphometric characteristics of the tumour, response to neoadjuvant treatment and long‐term outcomes in patients with locally advanced rectal cancers
Wang et al. c-Met, CREB1 and EGFR are involved in miR-493-5p inhibition of EMT via AKT/GSK-3β/Snail signaling in prostate cancer
CO2019011359A2 (en) System for predicting the prognosis and benefit of adjuvant chemotherapy for patients with stage II and III gastric cancer
Kato et al. DDX 39 acts as a suppressor of invasion for bladder cancer
Kachrilas et al. PI3K/AKT pathway genetic alterations and dysregulation of expression in bladder cancer
AR031457A1 (en) METHOD FOR DETERMINING A THERAPEUTIC REGIME THROUGH THE ANALYSIS OF GENE EXPRESSION IN PRIMARY TUMORS
CO2022012196A2 (en) Compositions and methods for kallikrein (klkb1) gene editing
Jankowski et al. Merkel cell carcinoma: is this a true carcinoma?
Guenin et al. Interleukin‐32 expression is associated with a poorer prognosis in head and neck squamous cell carcinoma
MX2020011287A (en) Selecting patients for therapy with adenosine signaling inhibitors.
Zhang et al. Comparative proteomics analysis of chronic atrophic gastritis: changes of protein expression in chronic atrophic gastritis without Helicobacter pylori infection
MX2020004530A (en) Product and process for employing gc7 (n1-guanyl-1,7-diaminohepta ne) based antigen binding conjugates in cancer therapy.
AR043398A1 (en) METHODS OF DETERMINATION OF A CHEMOTHERAPEUTIC REGIME BASED ON THE LOSS OF HETEROCIGOSITY IN THE PLACE OF TIMIDYLATE SYNTHEASE
Park et al. Poorly differentiated histologic grade correlates with worse survival in SMAD4 negative pancreatic adenocarcinoma patients

Legal Events

Date Code Title Description
FB Suspension of granting procedure